Literature DB >> 21674121

Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis.

M Isola1, V Ferrari, A Miolo, F Stabile, D Bernardini, P Carnier, R Busetto.   

Abstract

OBJECTIVE: To measure the concentrations of nerve growth factor (NGF) in the synovial fluid from normal dogs and dogs with osteoarthritis (OA) secondary to common joint disorders.
METHODS: Nerve growth factor synovial concentrations were measured by ELISA assay in 50 dogs divided into three groups: 12 healthy, 16 affected by acute lameness within seven days before enrolment, and 22 with chronic lameness persisting by more than one month before enrolment and accompanied by radiological signs of OA. Both acute and chronic lameness were secondary to orthopaedic diseases involving the shoulder, elbow and stifle joints. Nerve growth factor synovial concentrations were compared between means for healthy and acute groups and between the three groups using an F-test. Significance level was set at p <0.05.
RESULTS: Nerve growth factor was detected in all canine synovial fluid samples. However, the mean synovial NGF concentration of healthy dogs (3.65 ± 2.18 pg/ml) was not significantly different from the mean value in dogs with acute lameness (6.45 ± 2.45 pg/ml) (p = 0.79). Conversely, the mean synovial NGF concentration in dogs with chronic lameness (20.19 ± 17.51 pg/ml) was found to be significantly higher than that found in healthy dogs (p <0.01). CLINICAL SIGNIFICANCE: This study demonstrates for the first time the presence of NGF in canine synovial fluid and its increased concentrations in dogs with chronic lameness compared to healthy dogs and dogs with acute lameness. The association between chronic lameness and raised synovial concentrations may suggest an involvement of NGF in OA inflammation and chronic pain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674121     DOI: 10.3415/VCOT-10-04-0051

Source DB:  PubMed          Journal:  Vet Comp Orthop Traumatol        ISSN: 0932-0814            Impact factor:   1.358


  14 in total

1.  A fully caninised anti-NGF monoclonal antibody for pain relief in dogs.

Authors:  David P Gearing; Elena R Virtue; Robert P Gearing; Alexander C Drew
Journal:  BMC Vet Res       Date:  2013-11-09       Impact factor: 2.741

2.  Screening the role of pronociceptive molecules in a rodent model of endometriosis pain.

Authors:  Pedro Alvarez; Jon D Levine
Journal:  J Pain       Date:  2014-04-20       Impact factor: 5.820

Review 3.  Biologic agents in osteoarthritis: hopes and disappointments.

Authors:  Xavier Chevalier; Florent Eymard; Pascal Richette
Journal:  Nat Rev Rheumatol       Date:  2013-04-02       Impact factor: 20.543

Review 4.  Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.

Authors:  Anne-Marie Malfait; Rachel E Miller; Joel A Block
Journal:  Pharmacol Ther       Date:  2020-04-18       Impact factor: 12.310

Review 5.  A Mechanism-Based Approach to the Management of Osteoarthritis Pain.

Authors:  Ezra Cohen; Yvonne C Lee
Journal:  Curr Osteoporos Rep       Date:  2015-12       Impact factor: 5.096

Review 6.  Nerve growth factor: an update on the science and therapy.

Authors:  M F Seidel; B L Wise; N E Lane
Journal:  Osteoarthritis Cartilage       Date:  2013-09       Impact factor: 6.576

7.  Expression of nociceptive ligands in canine osteosarcoma.

Authors:  S Shor; B A Fadl-Alla; H C Pondenis; X Zhang; K L Wycislo; S Lezmi; T M Fan
Journal:  J Vet Intern Med       Date:  2015-01-08       Impact factor: 3.333

Review 8.  Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.

Authors:  Shun-Li Kan; Yan Li; Guang-Zhi Ning; Zhi-Fang Yuan; Ling-Xiao Chen; Ming-Chao Bi; Jing-Cheng Sun; Shi-Qing Feng
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

9.  Measurements of C-reactive protein (CRP) and nerve-growth-factor (NGF) concentrations in serum and urine samples of dogs with neurologic disorders.

Authors:  Ulrike Kordass; Regina Carlson; Veronika Maria Stein; Andrea Tipold
Journal:  BMC Vet Res       Date:  2016-01-08       Impact factor: 2.741

10.  A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.

Authors:  Domenico Britti; Rosalia Crupi; Daniela Impellizzeri; Enrico Gugliandolo; Roberta Fusco; Carlo Schievano; Valeria Maria Morittu; Maurizio Evangelista; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  BMC Vet Res       Date:  2017-08-02       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.